CelLBxHealth plc (ANPCY) Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation Transcript

Operator

Good afternoon, and welcome to the CelLBxHealth plc investor presentation. [Operator Instructions]

And I would now like to hand you over to your CEO, Peter Collins. Good afternoon to you.

Peter Collins
Chief Executive Officer

Thank you. Good afternoon. Peter Collins, CEO at CelLBxHealth. I’m looking forward to share the latest around how we are moving the company forward with a new strategy and business plan.

On the call today, with myself presenting; my colleague, Sinead Armstrong, our FD. Would you like to introduce yourself, Sinead?

Sinead Armstrong

Yes. Sinead Armstrong. I have been with CelLBx, formerly ANGLE, over the last 25 years in various roles within finance. Doing my current role for about the last 7 to 8 years.

Peter Collins
Chief Executive Officer

Thank you, Sinead. Unfortunately, on this part of the presentation, our Executive Chairman, Dr. Jan Groen, can’t join us. But Jan has significant experience in the diagnostic industry. Some companies here he’s been involved in establishing from Europe and successfully transition them into the U.S. Two of them you can see there with Agendia and the company MDxHealth. And Jan and I have previously worked together.

From my own side, I spent the last 25 years or so in senior executive roles across either oncology, diagnostic or drug development and, in many cases, both, that included — includes a 5-year stint at GSK where I headed diagnostics, reporting to the Board, but also was part of their immunotherapy drug development group. So seeing both sides of the drug development story.

And I spent the last 10 years in liquid biopsy, primarily